This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Pharmacological Observations and Clinical Results in the Therapy of Hypertension

JOHN H. MOYER, M.D.

AMA Arch Intern Med. 1953;91(4):419-439.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PRELIMINARY observations,¹ reported three years ago, indicated that hydrallazine (1-hydrazinophthalazine; apresoline®)² possessed certain desirable features as a therapeutic agent for the treatment of hypertension. It reduced the blood pressure, increased renal blood flow,³ and was effective following oral administration. Since the original report we have extended our studies and now have available a longer follow-up evaluation (1 to 2 years). In addition, some pharmacological data have been collected concerning the mode of action of this compound. As the blood pressure is reduced, the heart is stimulated and cardiac output increases.⁴ The latter response is the cause of some of the most undesirable side reactions and is probably a result of central stimulation of certain components of the sympathetic nervous system, since it is abolished by sympathectomy⁵ and ganglionic blockade.⁶ The purpose of the present communication is to review some of the more important aspects of the pharmacology of this drug . . . [Full Text PDF of this Article]

Author Affiliations
HOUSTON, TEXAS

From the Baylor University College of Medicine, Departments of Pharmacology and Medicine; Dr. Moyer is Associate Professor of Pharmacology and Assistant Professor of Medicine.

Footnotes
Supported in part by a grant from the Houston Heart Association and the M. D. Anderson Foundation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?